# FDA Inspection 889103 - Mclaughlin Gormley King Company - July 30, 2014

Source: https://www.keypedia.com/records/fda_inspections/mclaughlin-gormley-king-company/c2213c8c-ffd2-4141-ba57-cc414cb494e5
Source feed: FDA_Inspections

> FDA Inspection 889103 for Mclaughlin Gormley King Company on July 30, 2014. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 889103
- Company Name: Mclaughlin Gormley King Company
- Inspection Date: 2014-07-30
- Classification: No Action Indicated (NAI)
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Office Name: Center for Drug Evaluation and Research

## Related Documents

- [FDA Inspection 1158364 - 2021-12-08](https://www.keypedia.com/records/fda_inspections/mclaughlin-gormley-king-company/20969a2d-6174-4d37-8c64-63269b1a110c)
- [FDA Inspection 950797 - 2015-11-12](https://www.keypedia.com/records/fda_inspections/mclaughlin-gormley-king-company/c2b3ee6c-f3e2-4db7-8acd-716a6137332c)
- [FDA Inspection 626858 - 2009-11-09](https://www.keypedia.com/records/fda_inspections/mclaughlin-gormley-king-company/040242cf-fc75-4dc4-ae9c-d12df316fab0)

Company: https://www.keypedia.com/companies/mclaughlin-gormley-king-company/7f808845-6551-41f6-bb65-9ce238910788

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c